Black Diamond Therapeutics, Inc. (BDTX) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1240570,
    "name": "Black Diamond Therapeutics, Inc.",
    "stock_name": "Black Diamond Therapeutics, Inc.",
    "full_name": "Black Diamond Therapeutics, Inc.",
    "name_url": "stocks-analysis/black-diamond-therapeutics-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "2.71",
    "chg": -0.74,
    "chgp": "-21.45%",
    "dir": -1,
    "prev_price": "3.45",
    "mcapval": "173.65",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2320,
    "indexname": "S&P 500",
    "isin": "US09203E1055",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "4.99 M",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/black-diamond-therapeutics-inc-1240570-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Black Diamond Therapeutics, Inc. Experiences Valuation Adjustment Amidst Competitive Market Landscape",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/black-diamond-therapeutics-changes-valuation-grade-from-attractive-to-very-attractive-3686316",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/BlackDiamondThe_valuationdot_3686316.png",
        "date": "2025-11-10 16:11:53",
        "description": "Black Diamond Therapeutics, Inc. has recently adjusted its valuation, showcasing a P/E ratio of 29 and a low PEG ratio of 0.27, indicating potential growth. The company demonstrates strong operational efficiency with a ROCE of 55.79%. Year-to-date, it has significantly outperformed the S&P 500, despite long-term challenges."
      },
      {
        "title": "Is Black Diamond Therapeutics, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-black-diamond-therapeutics-inc-overvalued-or-undervalued-3637837",
        "imagepath": "",
        "date": "2025-10-21 12:09:58",
        "description": "As of 17 October 2025, the valuation grade for Black Diamond Therapeutics, Inc. has moved from very attractive to attractive, indicating a shift in perception regarding its investment potential. The company appears to be overvalued, given its P/E ratio of 29, which is significantly higher than the peer average of approximately 12.03 for companies in the same sector. Additionally, the EV to EBITDA ratio stands at 0.54, while the PEG ratio is notably low at 0.27, suggesting that the stock may not be justified at its current price level.\n\nIn comparison to its peers, Black Diamond Therapeutics, Inc. has a higher valuation than Harpoon Therapeutics, Inc., which has a P/E of -28.51, and Selecta Biosciences, Inc., with a P/E of -6.42, both of which are considered risky investments. The company's recent stock performance shows a year-to-date return of 87.38%, significantly outperforming the S&P 500's return of 13.3..."
      },
      {
        "title": "Black Diamond Therapeutics Experiences Valuation Adjustment Amid Strong Market Performance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/black-diamond-therapeutics-changes-valuation-grade-from-very-attractive-to-attractive-3641089",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/BlackDiamondThe_valuationdot_3641089.png",
        "date": "2025-10-20 17:22:00",
        "description": "Black Diamond Therapeutics, Inc. has recently adjusted its valuation, showcasing a P/E ratio of 29 and a price-to-book value of 1.04. The company reports strong financial metrics, including a 55.79% ROCE and a PEG ratio of 0.27, indicating a favorable position compared to peers facing financial challenges."
      },
      {
        "title": "Is Black Diamond Therapeutics, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-black-diamond-therapeutics-inc-overvalued-or-undervalued-3634707",
        "imagepath": "",
        "date": "2025-10-20 12:27:19",
        "description": "As of 17 October 2025, the valuation grade for Black Diamond Therapeutics, Inc. has moved from very attractive to attractive, indicating a shift in perceived value. The company appears to be overvalued given its P/E ratio of 29, which is significantly higher than the peer average P/E of approximately 12.03. Additionally, the EV to EBITDA ratio stands at 0.54, while the industry peers are showing much lower or negative values, further suggesting that the stock may not be justified at its current price.\n\nIn comparison to its peers, Black Diamond Therapeutics, Inc. has a PEG ratio of 0.27, which is favorable, but this is overshadowed by the high P/E ratio. Notable peers include Harpoon Therapeutics, Inc. with a P/E of -28.51 and Selecta Biosciences, Inc. with a P/E of -6.42, both indicating that the industry is facing significant challenges. While specific return data is not available, the absence of a strong ..."
      },
      {
        "title": "Is Black Diamond Therapeutics, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-black-diamond-therapeutics-inc-overvalued-or-undervalued-3632246",
        "imagepath": "",
        "date": "2025-10-19 12:04:50",
        "description": "As of 17 October 2025, the valuation grade for Black Diamond Therapeutics, Inc. has moved from very attractive to attractive, indicating a shift in perceived value. The company appears to be overvalued, given its P/E ratio of 29, which is significantly higher than the peer average of approximately 12.03, and an EV to EBITDA ratio of 0.54, which is also above the industry benchmark. Additionally, the PEG ratio stands at 0.27, suggesting that while growth may be present, the current valuation does not adequately reflect it compared to peers.\n\nIn comparison to its peers, Harpoon Therapeutics, Inc. has a P/E ratio of -28.51, while Selecta Biosciences, Inc. shows a P/E of -6.42, indicating that Black Diamond is trading at a premium despite its attractive valuation grade. The company's recent stock performance has been mixed; while it has outperformed the S&P 500 with a year-to-date return of 87.38% compared to t..."
      },
      {
        "title": "Black Diamond Therapeutics Hits New 52-Week High of $4.11",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/black-diamond-therapeutics-hits-new-52-week-high-of-411-3608071",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/BlackDiamondThe_priceRelatedfactors_3608071.png",
        "date": "2025-10-09 20:24:13",
        "description": "Black Diamond Therapeutics, Inc. achieved a new 52-week high of USD 4.11 on October 8, 2025, despite a challenging year. The company reported positive results over the last three quarters, with significant operating cash flow and net profit, while maintaining strong institutional investor confidence."
      },
      {
        "title": "Black Diamond Therapeutics Hits New 52-Week High at $4.03",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/black-diamond-therapeutics-hits-new-52-week-high-at-403-3601684",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/BlackDiamondThe_priceRelatedfactors_3601684.png",
        "date": "2025-10-07 21:59:35",
        "description": "Black Diamond Therapeutics, Inc. achieved a new 52-week high of USD 4.03 on October 6, 2025, despite a challenging year marked by a 23.29% decline. The company, with a market cap of USD 174 million, has shown positive financial performance, including three consecutive profitable quarters."
      },
      {
        "title": "Black Diamond Therapeutics Hits New 52-Week High at $3.90",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/black-diamond-therapeutics-hits-new-52-week-high-at-390-3595674",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/BlackDiamondThe_priceRelatedfactors_3595674.png",
        "date": "2025-10-06 17:41:05",
        "description": "Black Diamond Therapeutics, Inc. achieved a new 52-week high of USD 3.90 on October 3, 2025, despite a challenging year. The company has reported positive results for three consecutive quarters, with significant operating cash flow and net profit, reflecting effective management and strong institutional ownership."
      },
      {
        "title": "Is Black Diamond Therapeutics, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-black-diamond-therapeutics-inc-technically-bullish-or-bearish-3547642",
        "imagepath": "",
        "date": "2025-09-20 19:59:49",
        "description": "As of 4 September 2025, the technical trend for Black Diamond Therapeutics, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. The monthly RSI indicates a bullish stance, and the daily moving averages are also bullish. However, the weekly KST is mildly bearish, and the monthly KST is bearish, which introduces some caution. The Bollinger Bands show a bullish signal on the weekly but are mildly bearish on the monthly. The overall stance is bullish, supported by strong OBV readings on both weekly and monthly timeframes.\n\nIn terms of performance, the stock has a year-to-date return of 56.54%, significantly outperforming the S&P 500's 12.22% return, although it has underperformed over the 1-year, 3-year, and 5-year periods compared to the benchmark...."
      }
    ],
    "total": 15,
    "sid": "1240570",
    "stock_news_url": "https://www.marketsmojo.com/news/black-diamond-therapeutics-inc-1240570"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Black Diamond Therapeutics, Inc. Experiences Valuation Adjustment Amidst Competitive Market Landscape

2025-11-10 16:11:53

Black Diamond Therapeutics, Inc. has recently adjusted its valuation, showcasing a P/E ratio of 29 and a low PEG ratio of 0.27, indicating potential growth. The company demonstrates strong operational efficiency with a ROCE of 55.79%. Year-to-date, it has significantly outperformed the S&P 500, despite long-term challenges.

Is Black Diamond Therapeutics, Inc. overvalued or undervalued?

2025-10-21 12:09:58

As of 17 October 2025, the valuation grade for Black Diamond Therapeutics, Inc. has moved from very attractive to attractive, indicating a shift in perception regarding its investment potential. The company appears to be overvalued, given its P/E ratio of 29, which is significantly higher than the peer average of approximately 12.03 for companies in the same sector. Additionally, the EV to EBITDA ratio stands at 0.54, while the PEG ratio is notably low at 0.27, suggesting that the stock may not be justified at its current price level. In comparison to its peers, Black Diamond Therapeutics, Inc. has a higher valuation than Harpoon Therapeutics, Inc., which has a P/E of -28.51, and Selecta Biosciences, Inc., with a P/E of -6.42, both of which are considered risky investments. The company's recent stock performance shows a year-to-date return of 87.38%, significantly outperforming the S&P 500's return of 13.3...

Black Diamond Therapeutics Experiences Valuation Adjustment Amid Strong Market Performance

2025-10-20 17:22:00

Black Diamond Therapeutics, Inc. has recently adjusted its valuation, showcasing a P/E ratio of 29 and a price-to-book value of 1.04. The company reports strong financial metrics, including a 55.79% ROCE and a PEG ratio of 0.27, indicating a favorable position compared to peers facing financial challenges.

Is Black Diamond Therapeutics, Inc. overvalued or undervalued?

2025-10-20 12:27:19

As of 17 October 2025, the valuation grade for Black Diamond Therapeutics, Inc. has moved from very attractive to attractive, indicating a shift in perceived value. The company appears to be overvalued given its P/E ratio of 29, which is significantly higher than the peer average P/E of approximately 12.03. Additionally, the EV to EBITDA ratio stands at 0.54, while the industry peers are showing much lower or negative values, further suggesting that the stock may not be justified at its current price. In comparison to its peers, Black Diamond Therapeutics, Inc. has a PEG ratio of 0.27, which is favorable, but this is overshadowed by the high P/E ratio. Notable peers include Harpoon Therapeutics, Inc. with a P/E of -28.51 and Selecta Biosciences, Inc. with a P/E of -6.42, both indicating that the industry is facing significant challenges. While specific return data is not available, the absence of a strong ...

Is Black Diamond Therapeutics, Inc. overvalued or undervalued?

2025-10-19 12:04:50

As of 17 October 2025, the valuation grade for Black Diamond Therapeutics, Inc. has moved from very attractive to attractive, indicating a shift in perceived value. The company appears to be overvalued, given its P/E ratio of 29, which is significantly higher than the peer average of approximately 12.03, and an EV to EBITDA ratio of 0.54, which is also above the industry benchmark. Additionally, the PEG ratio stands at 0.27, suggesting that while growth may be present, the current valuation does not adequately reflect it compared to peers. In comparison to its peers, Harpoon Therapeutics, Inc. has a P/E ratio of -28.51, while Selecta Biosciences, Inc. shows a P/E of -6.42, indicating that Black Diamond is trading at a premium despite its attractive valuation grade. The company's recent stock performance has been mixed; while it has outperformed the S&P 500 with a year-to-date return of 87.38% compared to t...

Black Diamond Therapeutics Hits New 52-Week High of $4.11

2025-10-09 20:24:13

Black Diamond Therapeutics, Inc. achieved a new 52-week high of USD 4.11 on October 8, 2025, despite a challenging year. The company reported positive results over the last three quarters, with significant operating cash flow and net profit, while maintaining strong institutional investor confidence.

Black Diamond Therapeutics Hits New 52-Week High at $4.03

2025-10-07 21:59:35

Black Diamond Therapeutics, Inc. achieved a new 52-week high of USD 4.03 on October 6, 2025, despite a challenging year marked by a 23.29% decline. The company, with a market cap of USD 174 million, has shown positive financial performance, including three consecutive profitable quarters.

Black Diamond Therapeutics Hits New 52-Week High at $3.90

2025-10-06 17:41:05

Black Diamond Therapeutics, Inc. achieved a new 52-week high of USD 3.90 on October 3, 2025, despite a challenging year. The company has reported positive results for three consecutive quarters, with significant operating cash flow and net profit, reflecting effective management and strong institutional ownership.

Is Black Diamond Therapeutics, Inc. technically bullish or bearish?

2025-09-20 19:59:49

As of 4 September 2025, the technical trend for Black Diamond Therapeutics, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. The monthly RSI indicates a bullish stance, and the daily moving averages are also bullish. However, the weekly KST is mildly bearish, and the monthly KST is bearish, which introduces some caution. The Bollinger Bands show a bullish signal on the weekly but are mildly bearish on the monthly. The overall stance is bullish, supported by strong OBV readings on both weekly and monthly timeframes. In terms of performance, the stock has a year-to-date return of 56.54%, significantly outperforming the S&P 500's 12.22% return, although it has underperformed over the 1-year, 3-year, and 5-year periods compared to the benchmark....

View All News